Burosumab
Approved for a growth disorderHeight measured in peopleBy injectionAntibodyAlso Crysvita
A manufactured antibody that sticks to the hormone FGF23 and stops it reaching the kidney, so the body keeps phosphate instead of losing it in urine.
Fully human monoclonal antibody against FGF23, given subcutaneously. FDA approved in April 2018, the first drug for X-linked hypophosphataemia; the age floor was lowered in 2019 and tumour-induced osteomalacia was added in 2020. The label covers XLH in adults and children 6 months and older, and FGF23-related hypophosphataemia in tumour-induced osteomalacia from phosphaturic mesenchymal tumours that cannot be curatively resected or localised, in adults and children 2 years and older.
Risks. More treatment-related side effects were reported on it than on the older treatment, and the phosphate and vitamin D medicines have to be stopped before it is begun.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.